SLC5A2 and kidney disorder: In addition, SGLT2 inhibitors can suppress the nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome [11,12], a key regulator of inflammation associated with ageing and heart and kidney disease progression.